MA35643B1 - Inhibiteur de cetp d'oxazolidinone bicyclique condensée - Google Patents
Inhibiteur de cetp d'oxazolidinone bicyclique condenséeInfo
- Publication number
- MA35643B1 MA35643B1 MA37024A MA37024A MA35643B1 MA 35643 B1 MA35643 B1 MA 35643B1 MA 37024 A MA37024 A MA 37024A MA 37024 A MA37024 A MA 37024A MA 35643 B1 MA35643 B1 MA 35643B1
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitor
- condensed bicyclic
- cetp
- bicyclic oxazolidinone
- oxazolidinone cetp
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des composés ayant la structure de formule i, comprenant des sels pharmaceutiquement acceptables des composés, qui sont des inhibiteurs de cetp et sont utiles pour élever le cholestérol-hdl, abaisser le cholestérol-ldl, et pour traiter ou prévenir l'athérosclérose.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161552592P | 2011-10-28 | 2011-10-28 | |
PCT/US2012/061842 WO2013063217A1 (fr) | 2011-10-28 | 2012-10-25 | Inhibiteur de cetp d'oxazolidinone bicyclique condensée |
Publications (1)
Publication Number | Publication Date |
---|---|
MA35643B1 true MA35643B1 (fr) | 2014-11-01 |
Family
ID=47143312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA37024A MA35643B1 (fr) | 2011-10-28 | 2014-05-13 | Inhibiteur de cetp d'oxazolidinone bicyclique condensée |
Country Status (41)
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
WO2012058187A1 (fr) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | Inhibiteur de cetp substitué par des amines cycliques à base d'oxazolidinone |
GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
EP2934518B1 (fr) | 2012-12-19 | 2020-02-19 | Merck Sharp & Dohme Corp. | Inhibiteurs de la cetp spirocycliques |
WO2014099834A1 (fr) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Composés de thiazolidinone thérapeutiques |
CN105143193B (zh) * | 2013-01-31 | 2017-12-15 | 株式会社钟根堂 | 作为cetp抑制剂的联芳基或杂环联芳基取代的环己烯衍生化合物 |
GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
US9981970B2 (en) | 2013-07-30 | 2018-05-29 | Merck Sharp & Dohme Corp. | Bicyclic ureas and thiadiazolidine-1, 1-dioxides as CETP inhibitors |
EP3038465B1 (fr) * | 2013-08-30 | 2021-10-06 | Merck Sharp & Dohme Corp. | Formulation pharmaceutique orale d'omarigliptine |
WO2015054088A1 (fr) | 2013-10-10 | 2015-04-16 | Merck Sharp & Dohme Corp. | Indolines 3,3'-disubstituées utilisées comme inhibiteurs de la protéine de transfert du cholestérol estérifié |
EP3083642B1 (fr) * | 2013-12-17 | 2018-09-05 | Merck Sharp & Dohme Corp. | Isoxazolines bicycliques condensées utilisées comme inhibiteurs de la protéine de transfert du cholestérol estérifié |
AU2014381733B2 (en) | 2014-02-05 | 2020-09-03 | Newamsterdam Pharma B.V. | Cholesteryl ester transfer protein (CETP) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases |
JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
RU2715236C2 (ru) | 2014-03-26 | 2020-02-26 | Астекс Терапьютикс Лтд | Комбинации |
KR102479696B1 (ko) | 2014-03-26 | 2022-12-22 | 아스텍스 테라퓨틱스 리미티드 | Fgfr 억제제 및 igf1r 억제제의 조합물 |
EP3174537B1 (fr) | 2014-07-29 | 2021-06-23 | Merck Sharp & Dohme Corp. | Isoxazolines monocycliques utilisées comme inhibiteurs de la protéine de transfert des esters de cholestérol |
WO2016067194A1 (fr) * | 2014-10-27 | 2016-05-06 | Sun Pharmaceutical Industries Limited | Procédé de préparation d'anacetrapib et d'un intermédiaire de celui-ci |
KR20170087880A (ko) * | 2014-11-28 | 2017-07-31 | 코와 가부시키가이샤 | 의약 |
JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
EP3307672A4 (fr) * | 2015-06-12 | 2019-04-10 | Rhodia Operations | Nanoparticules hybrides contenant des dendrons, procédés de production de ces nanoparticules hybrides, et leurs utilisations |
EP3322420B1 (fr) * | 2015-07-13 | 2021-12-29 | Merck Sharp & Dohme Corp. | Hétérocycles bicycliques en tant qu'inhibiteurs de la protéine de transfert des esters de cholestérol |
ES2811845T3 (es) | 2015-09-23 | 2021-03-15 | Janssen Pharmaceutica Nv | Heterociclos tricíclicos para el tratamiento del cáncer |
BR112018005625B1 (pt) | 2015-09-23 | 2023-11-14 | Janssen Pharmaceutica N.V | Compostos derivados de quinolina, piridopirazina, naftiridina e quinazolinona, composições farmacêuticas que os compreende e uso dos mesmos |
CN106432053A (zh) * | 2016-09-17 | 2017-02-22 | 青岛云天生物技术有限公司 | 一种尼拉帕布中间体4‑(3s‑哌啶‑3‑基)溴苯的制备方法 |
CN106432058A (zh) * | 2016-09-17 | 2017-02-22 | 青岛云天生物技术有限公司 | 一种Niraparib中间体4‑(3S‑哌啶‑3‑基)苯胺的制备方法 |
CN111285894B (zh) * | 2018-12-10 | 2021-03-05 | 北京天一绿甫医药科技有限公司 | 用于制备软海绵素类化合物的中间体及其制备方法 |
CN110639018B (zh) * | 2019-11-14 | 2020-06-26 | 牡丹江医学院 | 一种防治老年性高血压的药物组合物及其用途 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4845079A (en) | 1985-01-23 | 1989-07-04 | Luly Jay R | Peptidylaminodiols |
US5066643A (en) | 1985-02-19 | 1991-11-19 | Sandoz Ltd. | Fluorine and chlorine statine or statone containing peptides and method of use |
US4894437A (en) | 1985-11-15 | 1990-01-16 | The Upjohn Company | Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties |
US4885292A (en) | 1986-02-03 | 1989-12-05 | E. R. Squibb & Sons, Inc. | N-heterocyclic alcohol renin inhibitors |
US4980283A (en) | 1987-10-01 | 1990-12-25 | Merck & Co., Inc. | Renin-inhibitory pepstatin phenyl derivatives |
US5089471A (en) | 1987-10-01 | 1992-02-18 | G. D. Searle & Co. | Peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents |
US5034512A (en) | 1987-10-22 | 1991-07-23 | Warner-Lambert Company | Branched backbone renin inhibitors |
US5063207A (en) | 1987-10-26 | 1991-11-05 | Warner-Lambert Company | Renin inhibitors, method for using them, and compositions containing them |
US5055466A (en) | 1987-11-23 | 1991-10-08 | E. R. Squibb & Sons, Inc. | N-morpholino derivatives and their use as anti-hypertensive agents |
US5036054A (en) | 1988-02-11 | 1991-07-30 | Warner-Lambert Company | Renin inhibitors containing alpha-heteroatom amino acids |
US5036053A (en) | 1988-05-27 | 1991-07-30 | Warner-Lambert Company | Diol-containing renin inhibitors |
DE3841520A1 (de) | 1988-12-09 | 1990-06-13 | Hoechst Ag | Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
US5106835A (en) | 1988-12-27 | 1992-04-21 | American Cyanamid Company | Renin inhibitors |
US5063208A (en) | 1989-07-26 | 1991-11-05 | Abbott Laboratories | Peptidyl aminodiol renin inhibitors |
US5098924A (en) | 1989-09-15 | 1992-03-24 | E. R. Squibb & Sons, Inc. | Diol sulfonamide and sulfinyl renin inhibitors |
US5104869A (en) | 1989-10-11 | 1992-04-14 | American Cyanamid Company | Renin inhibitors |
US5114937A (en) | 1989-11-28 | 1992-05-19 | Warner-Lambert Company | Renin inhibiting nonpeptides |
US5095119A (en) | 1990-03-08 | 1992-03-10 | American Home Products Corporation | Renin inhibitors |
US5075451A (en) | 1990-03-08 | 1991-12-24 | American Home Products Corporation | Pyrrolimidazolones useful as renin inhibitors |
US5064965A (en) | 1990-03-08 | 1991-11-12 | American Home Products Corporation | Renin inhibitors |
US5071837A (en) | 1990-11-28 | 1991-12-10 | Warner-Lambert Company | Novel renin inhibiting peptides |
AU1856997A (en) | 1996-02-02 | 1997-08-22 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
CA2415742A1 (fr) | 2000-07-25 | 2002-01-31 | Merck & Co., Inc. | Indoles n-substitues utiles pour le traitement du diabete |
CA2434491A1 (fr) | 2001-01-30 | 2002-08-08 | Merck & Co., Inc. | Acyl-sulfamides pour le traitement de l'obesite, du diabete et des troubles lipidiques |
WO2003011824A1 (fr) | 2001-07-31 | 2003-02-13 | Bristol-Myers Squibb Company | Modulateurs bicycliques de la fonction du recepteur androgene |
ES2342596T3 (es) | 2002-08-29 | 2010-07-09 | MERCK SHARP & DOHME CORP. | Indoles con actividad anti-diabetica. |
AU2003260085B2 (en) | 2002-08-29 | 2008-09-11 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
WO2004066963A2 (fr) | 2003-01-17 | 2004-08-12 | Merck & Co., Inc. | Derives de n-cyclohexylaminocarbonyl benzenesulfonamide |
AU2004249138B2 (en) * | 2003-06-12 | 2008-07-17 | Merck Sharp & Dohme Corp. | Mitotic kinesin inhibitors |
WO2005018638A1 (fr) | 2003-08-13 | 2005-03-03 | Merck & Co., Inc. | Inhibiteurs mitotiques de la kinesine |
BRPI0508966A (pt) | 2004-03-26 | 2007-08-21 | Lilly Co Eli | composto, composição farmacêutica, e, uso de um composto |
CN1938320A (zh) * | 2004-03-26 | 2007-03-28 | 伊莱利利公司 | 用于治疗异常脂肪血症的化合物和方法 |
JP4922924B2 (ja) | 2004-04-13 | 2012-04-25 | メルク・シャープ・エンド・ドーム・コーポレイション | Cetp阻害薬 |
DOP2005000123A (es) | 2004-07-02 | 2011-07-15 | Merck Sharp & Dohme | Inhibidores de cetp |
CN101384590A (zh) * | 2005-12-22 | 2009-03-11 | 先灵公司 | 作为凝血酶受体拮抗剂的唑并异喹啉 |
JP5199121B2 (ja) * | 2005-12-30 | 2013-05-15 | メルク・シャープ・エンド・ドーム・コーポレイション | Cetp阻害剤 |
AU2006335108B2 (en) | 2005-12-30 | 2011-04-07 | Merck Sharp & Dohme Corp. | CETP inhibitors |
EP2029560B1 (fr) | 2005-12-30 | 2013-04-24 | Merck Sharp & Dohme Corp. | Derives de 1,3-oxazolidin-2-one en tant qu'inhibiteurs de cetp |
WO2010039474A1 (fr) | 2008-10-01 | 2010-04-08 | Merck Sharp & Dohme Corp. | Promédicaments d'inhibiteurs de cetp à base d'oxazolidinone |
WO2011028395A1 (fr) | 2009-08-24 | 2011-03-10 | Merck Sharp & Dohme Corp. | Inhibiteur de cetp à base de pyridyl oxazolidinone |
WO2012058187A1 (fr) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | Inhibiteur de cetp substitué par des amines cycliques à base d'oxazolidinone |
US9353101B2 (en) | 2012-05-02 | 2016-05-31 | Merck Sharp & Dohme Corp. | Cyclic amine substituted heterocyclic CETP inhibitors |
-
2012
- 2012-10-21 JO JOP/2012/0317A patent/JO3210B1/ar active
- 2012-10-25 EP EP12781551.2A patent/EP2771345B1/fr active Active
- 2012-10-25 RS RS20161003A patent/RS55420B1/sr unknown
- 2012-10-25 GE GEAP201213478A patent/GEP20166434B/en unknown
- 2012-10-25 PT PT127815512T patent/PT2771345T/pt unknown
- 2012-10-25 AU AU2012328759A patent/AU2012328759B2/en not_active Ceased
- 2012-10-25 MX MX2014005074A patent/MX345222B/es active IP Right Grant
- 2012-10-25 ME MEP-2016-268A patent/ME02557B/fr unknown
- 2012-10-25 BR BR112014010204A patent/BR112014010204A2/pt not_active Application Discontinuation
- 2012-10-25 ES ES12781551.2T patent/ES2604953T3/es active Active
- 2012-10-25 KR KR1020147013895A patent/KR101686308B1/ko active IP Right Grant
- 2012-10-25 DK DK12781551.2T patent/DK2771345T3/en active
- 2012-10-25 LT LTEP12781551.2T patent/LT2771345T/lt unknown
- 2012-10-25 WO PCT/US2012/061842 patent/WO2013063217A1/fr active Application Filing
- 2012-10-25 HU HUE12781551A patent/HUE030568T2/en unknown
- 2012-10-25 JP JP2014538988A patent/JP5658427B2/ja not_active Expired - Fee Related
- 2012-10-25 PE PE2014000616A patent/PE20141230A1/es not_active Application Discontinuation
- 2012-10-25 IN IN3073CHN2014 patent/IN2014CN03073A/en unknown
- 2012-10-25 US US13/660,010 patent/US8871738B2/en active Active
- 2012-10-25 CN CN201280052931.5A patent/CN103958524B/zh not_active Expired - Fee Related
- 2012-10-25 SG SG11201401884PA patent/SG11201401884PA/en unknown
- 2012-10-25 UA UAA201405743A patent/UA114612C2/uk unknown
- 2012-10-25 EA EA201490889A patent/EA026123B1/ru not_active IP Right Cessation
- 2012-10-25 SI SI201230757A patent/SI2771345T1/sl unknown
- 2012-10-25 PL PL12781551T patent/PL2771345T3/pl unknown
- 2012-10-25 CA CA2852743A patent/CA2852743C/fr not_active Expired - Fee Related
- 2012-10-26 TW TW101139812A patent/TWI601731B/zh not_active IP Right Cessation
- 2012-10-26 AR ARP120104037A patent/AR088565A1/es unknown
-
2014
- 2014-04-13 IL IL232130A patent/IL232130A/en not_active IP Right Cessation
- 2014-04-15 TN TNP2014000158A patent/TN2014000158A1/en unknown
- 2014-04-22 CO CO14085787A patent/CO6940419A2/es active IP Right Grant
- 2014-04-25 ZA ZA2014/03091A patent/ZA201403091B/en unknown
- 2014-04-25 DO DO2014000086A patent/DOP2014000086A/es unknown
- 2014-04-28 NI NI201400034A patent/NI201400034A/es unknown
- 2014-04-28 CL CL2014001090A patent/CL2014001090A1/es unknown
- 2014-05-13 MA MA37024A patent/MA35643B1/fr unknown
- 2014-05-28 EC ECIEPI20142458A patent/ECSP14002458A/es unknown
- 2014-05-28 CR CR20140256A patent/CR20140256A/es unknown
- 2014-09-04 HK HK14109018.3A patent/HK1195558A1/zh not_active IP Right Cessation
- 2014-09-08 US US14/480,202 patent/US9346825B2/en active Active
- 2014-09-18 ZA ZA2014/06833A patent/ZA201406833B/en unknown
-
2016
- 2016-11-21 HR HRP20161541TT patent/HRP20161541T1/hr unknown
- 2016-12-16 CY CY20161101308T patent/CY1118464T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA35643B1 (fr) | Inhibiteur de cetp d'oxazolidinone bicyclique condensée | |
PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
MA38050B1 (fr) | Inhibiteurs de gdf-8 | |
TW200639166A (en) | Amino-pyridines as inhibitors of β-secretase | |
EA200900152A1 (ru) | Ингибиторы пирролотриазинкиназы | |
MA37712B1 (fr) | Inhibiteurs macrocycliques de virus flaviviridae | |
EA201500362A1 (ru) | Ингибиторы rho-киназы | |
MA33492B1 (fr) | Inhibiteurs de bace | |
TN2015000347A1 (fr) | Azabenzimidazoles servant d'inhibiteurs d'isoenzymes pde4 pour le traitement de troubles du snc et d'autres troubles | |
EA201200373A1 (ru) | Соединения и композиции в качестве ингибиторов протеинкиназ | |
MX2009010057A (es) | Compuesto de amino-5-[4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de beta-secretasa. | |
HK1154002A1 (en) | Imidazopyridazinecarbonitriles useful as kinase inhibitors | |
UA108087C2 (uk) | Тверді форми n-(4-(7-азабіцикло[2.2.1]гептан-7-іл)-2-(трифторметил)феніл)-4-оксо-5-(трифторметил)-1,4-дигідрохінолін-3-карбоксаміду | |
MA33304B1 (fr) | Indazoles substitués par oxazole comme inhibiteurs de pi3-kinase | |
MX2013005826A (es) | Benzoxazepinas como inhibidores de fosfatidilinositol 3-cinasa/objetivo de rapamicina en mamiferos (p13k/mtor) y metodos de uso y fabricacion. | |
MX2013012776A (es) | Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina. | |
MX2012002752A (es) | Compuestos de heteroarilo como inhibidores de cinasa. | |
EA201390711A1 (ru) | Гидроксиамидные соединения пиримидина в качестве ингибиторов деацетилаз белков и способы их применения | |
UA102251C2 (ru) | Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера | |
NO20065148L (no) | Monocykliske heterocykler som kinase inhibitorer | |
EA201100391A1 (ru) | Соединения, ингибирующие активность семикарбазид-чувствительной аминооксидазы | |
EA201691759A1 (ru) | Композиции и способы лечения легочной гипертензии | |
MX2012015098A (es) | Compuestos heterociclicos fusionados como inhibidores de fosfodiesterasas (pdes). | |
EP2595482A4 (fr) | Inhibiteurs de l'aldostérone synthase | |
MA39152B1 (fr) | Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine |